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Abstract
Background: Long-term improvement of health-related quality of life (HRQoL) in schizophrenia may improve
adherence and reduce relapse and rehospitalization. This analysis examines long-term changes in HRQoL among
patients with schizophrenia switched to lurasidone from other antipsychotics.
Methods: Patients who completed an open-label 6-week switch study continued on lurasidone for an additional
24-weeks. HRQoL was measured using the self-reported Personal Evaluation of Transitions in Treatment (PETiT) scale
and Short-Form 12 (SF-12) questionnaire. The PETiT assessed HRQoL via total and domain scores (adherence-related
attitude and psychosocial functioning). The SF-12 assessed patients’ mental and physical component summary
scores (MCS and PCS). Mean changes from the initial baseline were calculated at extension baseline and extension
endpoint using analysis of covariance models. Analyses were further stratified by prior antipsychotic medication and
responder status; responders were defined as having a ≥20 % improvement in Positive and Negative Syndrome
Scale during the first 6-weeks of treatment.
Results: The analysis included 144 patients with PETIT or SF-12 data who received ≥1 dose of lurasidone. Mean
(standard deviation) PETiT total score improved significantly from 34.9 (9.3) at baseline to 39.5 (8.9) at extension
baseline and 39.1 (9.0) at extension endpoint, representing improvements of 4.5 (7.9) and 5.1 (7.2) points, respectively
(both p < 0.001). Significant improvements in adherence-related attitude and psychosocial functioning were observed
at extension baseline and extension endpoint (all p < 0.001). Improvement in SF-12 MCS score was observed at
extension baseline and endpoint, and PCS score at extension endpoint (all p < 0.01). Patients who switched from
quetiapine and aripiprazole showed significant improvement of PETiT total score and adherence-related attitude
at extension baseline and extension endpoint. In addition, patients who switched from quetiapine, risperidone,
aripiprazole, or ziprasidone showed significant improvement in MCS scores from baseline to extension endpoint.
Responders to lurasidone demonstrated greater improvement in PETiT total, psychosocial functioning, and MCS
scores at extension baseline than nonresponders.
Conclusions: After switching to lurasidone, patients with schizophrenia experienced HRQoL improvements that
were sustained for an additional 24 weeks of treatment. Further study is warranted to understand the implications of
these improvements in terms of employment, adherence, relapse, and rehospitalization.
Trial registration: Clinical trials.gov identifier NCT01143090 (June 10th, 2010).
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Background
Schizophrenia is a severe, chronic, and debilitating dis-
order characterized by psychosis, behavioral dysfunction,
and cognitive impairment. These manifestations not only
impact the patient but also family, friends, and caregivers,
as well as the healthcare system and society [1].
The prominent symptomatic manifestations of schizo-
phrenia have been associated with considerable declines
in health-related quality of life (HRQoL) [2–7]. HRQoL
has been defined as the functional effect of a medical
condition and its treatment on patient well-being [8–10].
This subjective and multidimensional outcome encom-
passes physical and occupational functioning, psychological
state, social interactions, and somatic sensations [9].
HRQoL can be measured using a variety of general and
disease-specific instruments that are typically patient-
reported [11, 12]. For patients with schizophrenia,
HRQoL and functioning are inversely associated with
relapse and hospitalization rates, medication nonadherence,
and treatment costs [13–18].
Treatment with atypical antipsychotics, the standard
pharmacological treatment for schizophrenia, has led to
improvements in HRQoL [19–22]. However, the impact
of each drug in this class is variable, in part because of
their unique clinical pharmacology and tolerability pro-
files [12, 23–25]. Identification of the optimal thera-
peutic regimen for each patient often requires switching
between atypical antipsychotics to maximize relief from
acute symptoms, improve long-term HRQoL and func-
tioning, and minimize adverse effects [26, 27].
Given the importance of HRQoL in patients with
schizophrenia, long-term studies can provide a broader
picture of antipsychotic effectiveness in clinical practice.
While results from clinical trials indicate that switching
between antipsychotics can be performed in a relatively
safe manner [20, 25–31], only a few studies have reported
on the long-term (>6 months) effects of switching between
treatments on HRQoL, patient attitude towards medica-
tion, or health status [25, 29, 32–36].
The efficacy, tolerability, and safety of lurasidone
hydrochloride, a second-generation atypical antipsychotic
approved for the treatment of adults with schizophrenia,
have been demonstrated in published clinical trials [37–41]
and summarized in review articles [42, 43]. A recent open-
label clinical trial demonstrated that switching clinically
stable yet symptomatic patients with schizophrenia or
schizoaffective disorder to 6 weeks of treatment with
lurasidone was well tolerated (i.e., low rates of patient
discontinuation) and associated with improvements on
the Positive and Negative Syndrome Scale [PANSS], the
Clinical Global Impressions-Severity [CGI-S], and the
Calgary Depression Scale for Schizophrenia [CDSS]) [44].
The 6-week trial also showed statistically significant im-
provements in overall HRQoL, adherence-related attitude,
and psychosocial functioning and stabilization or improve-
ment of health status using the self-reported Personal
Evaluations of Transitions in Treatment (PETiT) scale and
Short-form 12 (SF-12) instruments [45–47]. In a 24-week
extension of the core 6-week switch trial, sustained effi-
cacy was demonstrated on the PANSS, CGI-S, and CDSS,
as was tolerability as measured by low rates [<10 %] of ad-
verse events [AEs] and AE-related discontinuation and a
lack of consistent, clinically relevant changes in metabolic
outcomes [48]. The current follow-up analysis examines
long-term HRQoL data for clinically stable yet symptom-
atic patients with schizophrenia switched to lurasidone in




The study design and primary outcomes of this clinical
trial, which was conducted at 26 sites in the United
States, have been previously published [44, 48]. In brief,
the trial included patients who completed a 6-week core
trial after being switched to lurasidone from their current
antipsychotic therapy and continued on lurasidone in an
open-label 24-week extension study (Fig. 1). Both the 6-
week core and 24-week extension studies were approved
by the Copernicus Group Independent Review Board
and were conducted in accordance with Good Clinical
Practices as required by the International Conference on
Harmonization guidelines. All patients provided informed
consent to participate in the study.
Study patients
The trial included clinically stable but symptomatic adult
outpatients aged ≥18 years who met the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV-TR)
criteria for a primary diagnosis of schizophrenia or schi-
zoaffective disorder [44]. Patients were judged to be stable
by the investigators based on the following criteria: a
CGI-S score ≤4 at screening and baseline, a stable dose
of pre-switch antipsychotic (s) for ≥28 days prior to
screening, and no exacerbation of schizophrenia or
schizoaffective disorder for ≥8 weeks prior to screening.
Patients had at least a partial response to an antipsychotic
and were stable at a dose consistent with product labeling.
Unstable patients or those known to be treatment-resistant
were excluded from the study. Patients were also required
to have a clinically relevant reason for changing antipsy-
chotics as determined by study investigators (i.e., insuffi-
cient efficacy and/or safety or tolerability concerns while on
current medication despite attempts at optimization).
Patients who completed the 6-week core trial were
continued on the same dose of lurasidone in the 24-week
extension study (Fig. 1), providing a total of 30 weeks
of data for analysis [48]. Lurasidone was flexibly dosed
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between 40 mg/day and 120 mg/day as clinically indi-
cated, starting on Day 7, with dose adjustments occur-
ring at weekly intervals as required. Additional details
of the study design, patient inclusion criteria, and pri-
mary results of the 24-week extension study have been
published by Citrome and colleagues [48].
HRQoL was evaluated in the current analysis using
two subjective patient-reported outcome measures, the
disease-specific PETiT scale [46] and the generic SF-12
Health Survey [47]. These measures were included as
secondary endpoints in both the core and extension stud-
ies. Both of these measures have been used previously in
the evaluation of HRQoL in patients with schizophrenia/
schizoaffective disorder [20, 49–51].
Outcome measures
PETiT scale
The PETiT scale is a validated, disease-specific, 30-item
instrument designed to measure the impact of treatment
on self-perceived subjective aspects of HRQoL in schizo-
phrenia patients who are receiving antipsychotic drug
therapy [46]. The scale assesses two highly relevant
domains for schizophrenia: adherence-related attitude
(includes six items reflecting adherence and feelings
towards medication) and psychosocial functioning (24
items describing patient characteristics such as clarity,
energy, concentration, functioning, sex drive, and mem-
ory). Psychosocial functioning can be assessed further
within four subdomains: social functioning (four items on
trust, confidence, and interactions), activity (seven items
reflecting energy and ability to conduct daily tasks), cogni-
tive (seven items on clarity, concentration, and communi-
cation), and dysphoria (six items on happiness, future, and
self-esteem). Each item on the PETiT scale is assigned a
rating of 0, 1, or 2, where 0 denotes worsened HRQoL and
2 denotes improved HRQoL. The PETiT total score
ranges from 0 to 60, with higher scores denoting better
patient HRQoL. The scale has high internal consistency
(Cronbach’s alpha = 0.92) and high test-retest reliability
(0.97; P < 0.001). Convergent validity has been demon-
strated with the PANSS, the global assessment of func-
tioning [GAF], and the quality of life scale [QLS] [46].
SF-12
The SF-12 survey is a generic 12-item instrument that is
commonly used to measure the health status of patients
with various diseases [47]. Scores on the SF-12 scale re-
flect changes in physical functioning, role limitations,
health perceptions, bodily pain, vitality, social function-
ing, and mental health based on patient responses to 12
questions. The survey yields two summary measures of
physical and mental health: the Physical Component
Summary (PCS) and Mental Component Summary (MCS)
scores. The SF-12 has been used in studies of patients with
schizophrenia, where the MCS and PCS were found to be
predictive of relapse and the MCS was predictive of remis-
sion [15, 52, 53].
Analysis
The intent-to-treat (ITT) population in the 24-week ex-
tension study was used for the PETiT and SF-12 ana-
lyses. This population was defined as 1) patients who
had received at least one dose of lurasidone, and 2) pa-
tients with non-missing values for PETiT or SF-12
scores at the core trial baseline and ≥1 post-baseline
value. The HRQoL measures were collected at baseline
in the core and extension studies and at Week 24 in the
extension study. Patients who had only a core study
baseline value but no extension study values (that is, all
change-from-baseline values were missing), were ex-
cluded from the ITT analysis. Population sizes (N values)
for PETiT and SF-12 scores varied across study time
points because of variations in the availability of patient
scores.
Fig. 1 Design of the lurasidone open-label core and extension switch studies.* 144 of the 235 (61 %) patients included in the core 6-week study
of HRQoL were included
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Similar to the analyses performed in the previous
short-term evaluation of HRQoL [45], the current study
examined mean changes in PETiT and SF-12 scores
from study baseline to extension study baseline (6 weeks)
and to extension study endpoint (end of the additional
24 weeks of treatment) using analysis of covariance
(ANCOVA) models. Treatment and study center (pooled
where necessary) were fixed factors and baseline value
was a covariate. Changes were calculated for the PETiT
scale total score, its domains and subdomains, and the
SF-12 PCS and MCS scores for all patients switched to
lurasidone. Changes in PETiT total and SF-12 scores
were also analyzed by prior antipsychotic therapy for
medications received by ≥9 % of subjects to ensure a
minimal sample size for analysis.
The current study additionally evaluated PETiT (total
and domains) and SF-12 scores by responder status. A
“responder” was defined as a patient with a ≥20 % im-
provement on the PANSS total score during the initial
6-week study; a “nonresponder” was defined as a patient
with a <20 % improvement on the PANSS during this
timeframe. This response cutoff is commonly used in
evaluations of patients with schizophrenia, with a ≥20 %
early improvement being predictive of subsequent posi-
tive clinical outcomes [54–56].
Results
Patient demographics & baseline characteristics
Of the 198 patients who completed the core 6-week trial,
148 entered the 24-week extension study and received the
study medication. Of these patients, 144 (61 % of the 235
patients included in the 6-week HRQoL analysis) with data
on the PETiT scale or the SF-12 survey comprised the ITT
population for the current analysis of HRQoL. Among the
141 patients with PETiT total and domain scores at core
study baseline, 139 had PETiT scores at extension study
baseline and 95 had PETiT scores at extension study end-
point. Among the 143 patients who had SF-12 scores at
core study baseline and extension study baseline, 97 had
SF-12 scores at extension study endpoint.
Table 1 presents a summary of the baseline character-
istics for the ITT population. The majority of patients
were male (63.2 %) and the mean (standard deviation
[SD]) age at study entry was 42.6 (11.2) years. Close to
one-quarter (23.6 %) of patients switched to lurasidone
from quetiapine, 21.5 % from aripiprazole, 20.1 % from
risperidone, 13.2 % from ziprasidone, and 9.0 % from
olanzapine. The overall mean (SD) daily dose of lurasi-
done was 101.8 mg (77.6).
PETiT assessment
Total and domain scores
At core study baseline, the PETiT scale was found to
have high reliability based on a Cronbach’s alpha of 0.88.
The mean (SD) PETiT total score for all lurasidone pa-
tients improved from 34.9 (9.3) at core study baseline to
39.5 (8.9) at extension study baseline and 39.1 (9.0) at
extension study endpoint (Fig. 2; Table 2). This change
in scores represented statistically significant improve-
ments of 4.5 (7.9) and 5.1 (7.2) (both p < 0.001) at
6 weeks and after an additional 24 weeks of treatment,
respectively. Mean (SD) changes from core baseline to
extension study baseline and extension study endpoint




Mean age, years (SD) 42.6 (11.2)
Gender
Male, n (%) 91 (63.2)
Race, n (%)
Black or African American 92 (63.9)
White 46 (31.9)
Other 6 (4.2)
Mean age (SD) at initial onset of schizophrenia or
schizoaffective disorder (years)
24.2 (9.4)
DSM-IV Schizophrenia subtype diagnosis, n (%)a
295.10 Disorganized type 1 (0.7)
295.30 Paranoid type 70 (48.6)
295.60 Residual type 1 (0.7)
295.70 Schizoaffective disorder 55 (38.2)
295.90 Undifferentiated type 18 (12.5)









First-generation antipsychoticc 17 (11.8)
Mean (SD) daily dose of lurasidone (mg) 101.8 (77.6)
Employment status, n (%) N = 95d
Employed 14 (14.7)
Unemployed 81 (85.3)
Abbreviations: DSM-IV Diagnostic and Statistical Manual of Mental Disorders IV,
SD standard deviation
aPatients could have more than one DSM-IV schizophrenia subtype
of diagnosis
bPatients could be on multiple pre-switch antipsychotics
cFirst-generation antipsychotics included chlorpromazine, fluphenazine,
haloperidol, perphenazine, and tiotixene
dPatients with both PETiT and employment status data
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were also significant in the domains of adherence-related
attitude (1.2 [2.3] and 1.3 [2.5], respectively) and psycho-
social functioning (3.3 [6.5] and 3.8 [5.8], respectively) (all
p < 0.001) (Fig. 2; Table 2).
Patients additionally showed significant improvements
in three of the four subdomains of psychosocial function-
ing: scores for activity, cognitive, and dysphoria were higher
at both extension study baseline and extension study end-
point (Table 2; all p < 0.001). Scores for social functioning
remained comparable to those at core baseline.
Outcome by prior antipsychotic
Prior antipsychotics received by at least 9 % of patients
in the extension study included quetiapine, olanzapine,
risperidone, aripiprazole, and ziprasidone. Patients who
switched from any of these medications except olanza-
pine showed statistically significant improvements in the
PETiT total score from core baseline to extension baseline
(p ≤ 0.024) (Table 3). Subjects switched from quetiapine
and aripiprazole maintained this significant difference at
extension study endpoint (p ≤ 0.026). Improvements,
some of which were significant, in the PETiT domains
of adherence-related attitude and psychosocial functioning
were also observed, particularly for subjects switching from
quetiapine or aripiprazole. For subjects switched from olan-
zapine, increases in PETiT total and domain scores were
observed from core study baseline through extension study
endpoint (Table 3); however, these differences were either
not statistically significant or significance could not be esti-
mated as a result of small sample sizes.
Outcome by responder status
Responders to lurasidone (i.e., those having a ≥20 % im-
provement on the PANSS Total Score at Week 6 compared
with core study baseline) showed significantly greater
improvement in PETiT total (8.4 vs. 3.5, p = 0.01) and
psychosocial functioning (6.4 vs. 2.5, p = 0.014) scores from
core baseline to extension study baseline than nonre-
sponders (Table 4). Though not significant, responders also
showed greater improvement in PETiT total, adherence-re-
lated attitude domain, and psychosocial functioning do-
main scores than non-responders from core baseline to
extension study endpoint. Responders demonstrated
the greatest improvement in the PETiT total score
from core baseline to extension study baseline; this im-
provement was sustained at the extension study end-
point (8.4 vs. 8.0). While non-responders had modest
improvement in the PETiT total score from core baseline
to extension study baseline, their HRQoL continued to
improve over the course of treatment (i.e., at extension
study endpoint) with lurasidone (3.5 vs. 4.1).
SF-12 assessment
Summary scores
At core study baseline, the SF-12 summary scales were
found to have adequate reliability based on a Cronbach’s
alpha of 0.76 for the PCS and 0.74 for the MCS. The SF-
Fig. 2 Mean Changes in PETiT total and domain scores in patients switched to long-term lurasidone therapy
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12 results showed that health status improved or remained
stable between core baseline, extension baseline, and the
end of an additional 24 weeks of treatment (extension
study endpoint; Table 5). Changes on the MCS score were
statistically significant between the core and extension
baselines (mean [SD]: 4.8 [11.6], p < 0.001) and between
core baseline and extension study endpoint (6.3 [10.3],
p < 0.001). PCS scores were maintained between core
baseline and extension study baseline and showed sig-
nificant improvement from core baseline to extension
study endpoint (2.6 [7.9], p=0.001).
Outcome by prior antipsychotic
Analysis of subjects by prior antipsychotic agent also
showed improvement or maintenance of health status
following long-term switch to lurasidone, particularly on
the MCS (Table 6). Subjects switched from aripiprazole
or ziprasidone showed statistically significant improve-
ments on the MCS score between core and extension
baseline (mean change [SD]: 3.7 [8.4] and 7.7 [10.5], re-
spectively; both p = 0.039). Similarly, subjects switched
from quetiapine showed significant improvement on the
MCS score between core baseline and extension study
endpoint (Week 30) (5.3 [10.9], p = 0.030). In general, PCS
scores remained stable from core baseline through the end
of the study regardless of preswitch antipsychotic agents.
Outcome by responder status
Responders to lurasidone demonstrated greater improve-
ment on the MCS score than non-responders from core
baseline to extension study baseline (mean change: 11.3
vs. 3.0; p = 0.001). There was no statistically significant dif-
ference in improvement on the PCS score between re-
sponders and non-responders, both from core baseline to
extension baseline and from core baseline to extension
study endpoint (Table 7).
Discussion
The current study examined the long-term effects of
lurasidone on HRQoL among clinically stable yet symp-
tomatic patients with schizophrenia or schizoaffective
disorder switched to lurasidone. The majority of patients
Table 2 Mean changes in PETiT total, domain, and subdomain scores in patients switched to lurasidone
Core Study Baseline Extension Study Baseline
(6 weeks)
Extension Study Endpoint (end of
additional 24 weeks of treatment)
Number 141a 139b 95c
PETiT
TotalScore
Mean Score (SD) 34.9 (9.3) 39.5 (8.9) 39.1 (9.0)
Change from Core BL (SD) – 4.5 (7.9) 5.1 (7.2)




Mean Score (SD) 8.6 (2.2) 9.8 (1.9) 9.7 (1.8)
Change from Core BL (SD) – 1.2 (2.3) 1.3 (2.5)




Mean Score (SD) 26.3 (8.1) 29.7 (7.8) 29.4 (8.0)
Change from Core BL (SD) – 3.3 (6.5) 3.8 (5.8)




Mean Score (SD) 3.8 (1.3) 4.0 (1.5) 3.9 (1.4)
Change from Core BL (SD) – 0.1 (1.4) 0.2 (1.3)
p-value – 0.534 0.361
Activity Subdomain (7 items) Mean Score (SD) 7.8 (2.8) 8.7 (2.8) 8.5 (2.9)
Change from Core BL (SD) – 1.0 (2.6) 1.1 (2.6)




Mean Score (SD) 8.2 (2.9) 9.3 (2.7) 9.3 (2.4)
Change from Core BL (SD) – 1.1 (2.3) 1.3 (2.1)




Mean Score (SD) 6.6 (2.5) 7.7 (2.2) 7.6 (2.6)
Change from Core BL (SD) – 1.1 (2.1) 1.2 (2.0)
p-value – <0.001 <0.001
Abbreviations: BL baseline, PETiT Personal Evaluation of Transitions in Treatment, SD standard deviation
aNumber of patients with PETiT total and domain scores at core study baseline
bNumber of patients with PETiT total and domain scores at both core study baseline and extension study baseline
cNumber of patients with PETiT total and domain scores at both core study baseline and extension study endpoint
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Table 3 Mean changes in PETiT total and domain scores by prior medication in patients switched to long-term lurasidone therapy



































PETiT Total Score N 33a 32b 23c 12a 12b 8c 25a 25b 13c 28a 28b 22c 19a 19b 13c
Mean Score (SD) 30.1 (8.0) 35.8 (9.6) 34.0 (6.6) 40.3
(11.8)
43.1 (11.1) 41.4 (12.1) 36.4
(9.9)
40.9 (8.5) 39.4 (11.9) 35.5 (7.6) 40.1 (8.1) 41 (7.7) 35.5
(8.2)
40.9 (7.4) 39.5 (8.6)
Change from Core
BL (SD)
– 5.3 (9.1) 3.0 (6.0) – 1.6 (5.6) 3.1 (7.6) – 5 (7.5) 8.4 (9.6) – 4.4 (6.9) 5.5 (6.1) – 5.4 (7.4) 5.3 (7.2)




Mean Score (SD) 8.0 (2.2) 9.2 (2.3) 8.7 (2.0) 9.2
(2.4)
10.2 (1.7) 9.4 (1.7) 8.8
(2.1)
10.1 (1.7) 10.1 (2.2) 8.3 (2.1) 10.1 (1.7) 10.2 (1.4) 8.6
(2.0)
9.9 (1.9) 9.8 (1.9)
Change from Core
BL (SD)
– 1.3 (2.7) 0.9 (2.5) – 0.9 (2.1) 0.6 (1.8) – 1.3 (2.0) 1.8 (2.5) – 1.7 (2.1) 1.8 (2.5) – 1.3 (1.9) 1.2 (2.5)




Mean Score (SD) 22.1 (7.0) 26.6 (8.5) 25.3 (6.1) 31.1
(10)
32.8 (9.6) 32 (10.5) 27.6
(8.7)
30.8 (7.6) 29.4 (10.3) 27.3 (6.6) 30.0 (7.3) 30.8 (7.3) 26.9
(7.2)
31.1 (6.4) 29.7 (7.6)
Change from Core
BL (SD)
– 3.9 (7.5) 2.1 (4.4) – 0.7 (4.3) 2.5 (6.9) – 3.8 (6.6) 6.5 (8.0) – 2.7 (5.8) 3.7 (5.4) – 4.1 (6.2) 4.2 (5.3)
p-value – 0.011 0.083 – 0.200 NEd – 0.058 0.131 – 0.081 0.013 – 0.003 0.228
Abbreviations: BL baseline, EP endpoint, NE Not estimable, PETiT Personal Evaluation of Transitions in Treatment, SD standard deviation
Note: Extension study BL = 6-week follow-up; extension study BL = 30-week follow-up
aNumber of patients with PETiT total and domain scores at core study baseline
bNumber of patients with PETiT total and domain scores at both core study baseline and extension study baseline
cNumber of patients with PETiT total and domain scores at both core study baseline and extension study endpoint













showed improvements in HRQoL on the PETiT total and
SF-12 MCS scores from core baseline to extension study
baseline (6 weeks) and to extension study endpoint (end
of additional 24 weeks of treatment). Sustained improve-
ments were also demonstrated on the PETiT domains of
adherence-related attitude and psychosocial functioning
and the psychosocial subdomains of activity, cognition,
and dysphoria. Given that psychosocial functioning is a
key outcome measure in understanding the effects of a
successful treatment in schizophrenia [57], this finding of
sustained improvement during lurasidone therapy may
have significant clinical implications.
Subgroup analyses of the results by prior antipsychotic
and responder status further showed improvement of
HRQoL and functioning during both short- and long-term
treatment with lurasidone. Patients who switched from
any of the analyzed antipsychotics (quetiapine, olanzapine,
risperidone, aripiprazole, ziprasidone) generally showed
improvements from core baseline to extension study base-
line and/or extension study endpoint. These improve-
ments were most likely to be statistically significant in
patients switched from quetiapine or aripiprazole. While
the larger sample size of patients switching from these
therapies may have contributed to this finding, it is rea-
sonable to hypothesize that the reduced risk of sedation
[58, 59] and agitation [60, 61] associated with lurasidone
may have played a role. Responders to lurasidone generally
showed greater improvements on the PETiT scale and SF-
12 scores (MCS) than non-responders. The lack of statis-
tical significance between these groups for changes from
baseline to study endpoint may relate to small sample
sizes. Notably, while non-responders had only modest im-
provement on the PETiT total score during short-term
treatment, their HRQoL continued to improve during
Table 4 Mean changes in PETiT total and domain scores by responder status
Responders Non-responders








PETiT Total Score N 31a 31b 24c 110a 108b 71c
Mean Score (SD) 32.5 (8.4) 41.0 (10.4) 40.5 (9.6) 35.6 (9.5) 39.1 (8.4) 38.6 (8.8)
Change from Core BL (SD) – 8.4 (8.5) 8.0 (6.5) – 3.5 (7.4) 4.1 (7.1)
p-value (between group) – 0.010* 0.152** – – –
Adherence-related Attitude Domain Score Mean Score (SD) 8.1 (2.2) 10.1 (2.1) 10.0 (1.7) 8.8 (2.2) 9.7 (1.8) 9.6 (1.9)
Change from Core BL (SD) – 2.0 (2.2) 2.0 (2.2) – 0.9 (2.3) 1.0 (2.5)
p-value (between group) – 0.051* 0.318ˣ** – – –
Psychosocial Functioning Domain Score Mean Score (SD) 24.5 (7.3) 30.9 (8.8) 30.6 (8.5) 26.8 (8.2) 29.4 (7.5) 29.0 (7.8)
Change from Core BL (SD) – 6.4 (7.0) 6.0 (5.5) – 2.5 (6.1) 3.0 (5.7)
p-value (between group) – 0.014* 0.220** – – –
Note: Extension study BL = 6-week follow-up; extension study EP = end of additional 24 weeks of treatment
Abbreviations: BL baseline, EP endpoint, PETiT Personal Evaluation of Transitions in Treatment, SD standard deviation
aNumber of patients with PETiT total and domain scores at core study baseline
bNumber of patients with PETiT total and domain scores at both core study baseline and extension study baseline
cNumber of patients with PETiT total and domain scores at both core study baseline and extension study endpoint
*P-value comparing mean changes in PETiT total/domain scores from extension study baseline to core study baseline between responders and non-responders
**P-value comparing mean changes in PETiT total/domain scores from extension study endpoint to core study baseline between responders and non-responders
Table 5 Mean changes in SF-12 PCS and MCS scores
Core Study Baseline Extension Study Baseline (6 weeks) Extension Study Endpoint (end of
additional 24 weeks of treatment)
N 143a 143b 97c
PCS
Score
Mean Score (SD) 46.5 (10.6) 46.3 (10.1) 48.6 (9.4)
Change from Core Baseline (SD) – −0.3 (8.4) 2.6 (7.9)
p-value – 0.629 0.001
MCS
Score
Mean Score (SD) 41.8 (11.1) 46.5 (11.2) 47.3 (9.6)
Change from Core Baseline (SD) – 4.8 (11.6) 6.3 (10.3)
p-value – <0.001 <0.001
Abbreviations: MCS Mental Component Summary, PCS Physical Component Summary, SD standard deviation, SF-12 Short Form-12
aNumber of patients with SF-12 PCS and MCS scores at core study baseline
bNumber of patients with SF-12 PCS and MCS scores at both core study baseline and extension study baseline
cNumber of patients with SF-12 PCS and MCS scores at both core study baseline and extension study endpoint
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Table 6 Mean changes in SF-12 PCS and MCS scores by prior medication in patients switched to long-term lurasidone therapy






































N 30a 30b 25c 13a 13b 7δ 27a 27b 14c 31a 31b 20c 17a 17b 14c
Mean Score
(SD)






49.7 (8.6) 49.5 (6.5) 46.2
(11.1)
45.5 (11.0) 51.1 (9.1) 47.7
(10.5)
45.7 (10.6) 48.3 (9.7)
Change from
Core BL (SD)
– −1.0 (9.5) 0.9 (7.4) – −0.2 (5.0) 1.2 (10.1) – 1.9 (9.5) 2.0 (7.6) – −0.9 (7.8) 4.4 (7.7) – −1.8 (6.3) 2.5 (10.0)




N 30 30 25 13 13 7 27 27 14 31 31 20 17 17 14
Mean Score
(SD)








46.3 (11.0) 50.2 (9.9) 42.2
(8.1)
46.1 (9.2) 47.8 (9.3) 40.7
(8.8)
47.6 (9.6) 47.4 (8.9)
Change from
Core BL (SD)
– 4.8 (14.1) 5.3 (10.9) – 7.8 (9.1) 3.0 (5.3) – 4.7 (12.1) 10.2 (14.4) – 3.7 (8.4) 6.0 (9.3) – 7.7 (10.5) 5.8 (9.5)
p-value – 0.103 0.030 – 0.224 NEd – 0.057 <0.001 – 0.039 <0.001 – 0.039 0.035
Note: Extension study BL = 6-week follow-up; extension study BL = 30-week follow-up
Abbreviations: BL baseline, EP endpoint, NE Not estimable, MCS Mental Component Summary, PCS Physical Component Summary, SD standard deviation, SF-12 Short Form 12
aNumber of patients with SF-12 PCS/MCS scores at core study baseline
bNumber of patients with SF-12 PCS/MCS scores at both core study baseline and extension study baseline
cNumber of patients with SF-12 PCS/MCS scores at both core study baseline and extension study endpoint













longer-term therapy. This observation may arise because a
subset of these patients responded to treatment at a
slower pace (i.e., were “late responders”).
Guidelines from the National Institute for Health and
Care Excellence (NICE) and the American Psychiatric
Association emphasize the importance of choosing the
most appropriate antipsychotic drug and formulation
based on a patient’s needs and characteristics, rather
than relying solely on the main recognized properties of
different drug classes [62, 63]. A patient-centered ap-
proach to treatment selection may contribute to in-
creased adherence to therapy while reducing the risk of
adverse events, relapse, rehospitalization, and ultimately
poor HRQoL [52, 64, 65].
In addition to symptoms and treatment type, a schizo-
phrenia patient’s subjective response, perception, and at-
titude (i.e., how they perceive their clinical response
and/or adverse events) to therapy are suggested to play
key roles in HRQoL, adherence, and other long-term
outcomes [14, 66–71]. Adherence to antipsychotic ther-
apy is an ongoing problem in the management of schizo-
phrenia, with an estimated 40 % of patients being
partially or fully non-adherent [16, 71]. One-year data
from the Cost Utility of the Latest Schizophrenia Anti-
psychotic drugs in Schizophrenia (CUtLASS) randomized
controlled trial showed that improvements in adherence
led to greater quality of life [14]; similarly, 3 year results
from the European Schizophrenia Outpatients Health
Outcomes (EU-SOHO) study demonstrated that continu-
ous antipsychotic treatment was associated with important
HRQoL benefits [17]. Other studies indicate that im-
proved adherence can lead to greater treatment efficacy,
thereby reducing symptoms and the implications of in-
adequate therapy such as relapse and hospitalization
[13, 14, 16, 22, 52, 64, 65, 72, 73]. Given the significant
clinical and economic burden associated with psychiatric
relapses and hospitalizations in schizophrenia, the current
study’s finding of improved or maintained adherence-
related attitude after switching to lurasidone is of interest
and may have implications for future research on treat-
ment adherence with this therapy.
Switching antipsychotic therapies has been previously
found to lead to improvements in schizophrenia. A study
by Roussidis and colleagues showed that switching a
patient’s antipsychotic medication for reasons related to
lack of efficacy and/or tolerability was associated with a
significantly improved clinical benefit and increased ad-
herence to treatment [74]. Similarly, studies of patients
switching to olanzapine [28], quetiapine [29, 34], zipra-
sidone [33, 75], aripiprazole [76], long-acting injectable
risperidone [32, 77], or paliperidone [36] have reported
improvements in cognitive function, psychotic symptoms,
and/or tolerability during up to one year of treatment.
However, the current analysis is the only switch study to
examine long-term changes in subjective responses, toler-
ability, adherence-related attitude, and HRQoL using the
disease-specific PETiT assessment.
Overall, the results of the current study demonstrate
that switching to lurasidone after inadequate response
to current antipsychotic therapy is associated with im-
provements in HRQoL and health status, particularly in
responders to treatment. While HRQoL improvement was
observed among schizophrenia patients having switched
to lurasidone in the current analysis, the authors recognize
several limitations of the study. The study was an open-
label trial in which treatment was not masked to either pa-
tients or physicians. The results could reflect the passage
of time, as the lack of a parallel control group precluded
study of the impact of discontinuation of lurasidone.
Moreover, patients who discontinued the study may have
Table 7 Mean Changes in SF-12 PCS and MCS Scores by Responder Status
Responders Non-responders








N 31a 31b 25c 112a 112b 72c
PCS score Mean Score (SD) 46.4 (11.4) 47.4 (10.7) 48.9 (9.9) 46.6 (10.4) 46.0 (9.9) 48.4 (9.3)
Change from Core BL (SD) – 0.6 (9.6) 2.7 (6.7) – −0.5 (8.0) 2.5 (8.3)
p-value (between group) – 0.239* 0.643** – – –
MCS score Mean Score (SD) 38.9 (8.6) 49.6 (11.5) 48.5 (9.0) 42.6 (11.6) 45.6 (11.0) 46.9 (9.8)
Change from Core BL (SD) – 11.3 (10.1) 10.0 (10.1) – 3.0 (11.3) 5.0 (10.1)
p-value (between group) – 0.001* 0.280** – – –
Note: Extension study BL = 6-week follow-up; extension study BL = end of additional 24 weeks of treatment
Abbreviations: BL baseline, EP endpoint, NE Not estimable, MCS Mental Component Summary, PCS Physical Component Summary, SD standard deviation,
SF-12 Short Form 12
aNumber of patients with SF-12 PCS/MCS scores at core study baseline
bNumber of patients with SF-12 PCS/MCS scores at both core study baseline and extension study baseline
cNumber of patients with SF-12 PCS/MCS scores at both core study baseline and extension study endpoint
*P-value comparing mean changes in SF-12 PCS/MCS scores from extension study baseline to core study baseline between responders and non-responders
**P-value comparing mean changes in SF-12 PCS/MCS scores from extension study endpoint to core study baseline between responders and non-responders
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differed from those who completed the study. As with any
self-reported outcome, patient responses on the PETiT
and SF-12 may have been biased by patient’s expectation,
recall issues, or other aspects of the treatment experience.
Further, given the small sample sizes for the prior anti-
psychotic and responder analyses, interpretation of these
results may warrant caution. Finally, evaluation of PETiT
and SF-12 scores at multiple time points throughout the
trial rather than only at baseline, 6 weeks, and after an
additional 24 weeks of treatment would have provided a
more complete picture of lurasidone-induced changes in
HRQoL. Nevertheless, this switch trial provides important
guidance on clinical practice concerning switching pa-
tients to lurasidone in the context of long-term HRQoL
benefits.
Conclusions
In conclusion, the results of this follow-up study dem-
onstrated that stable yet symptomatic patients with
schizophrenia or schizoaffective disorder who switched
to lurasidone from other antipsychotics experienced
long-term improvements in HRQoL. When healthcare
providers continue to work with schizophrenia patients
to optimize treatment, long-term HRQoL gains can be
achieved. To our knowledge, this study is the first to
assess long-term HRQoL outcomes after switch to lura-
sidone, is one of only few antipsychotic switch studies
with a follow-up duration ≥6 months, and is the only
switch study to use the validated, disease-specific PETiT
scale. Further research is warranted to understand the
impact of lurasidone-related improvements in HRQoL
on medication adherence, relapse and rehospitalization
rates, employment status, and overall costs to the health
care system.
Abbreviations
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HRQoL, health-related quality of life; ITT, intention to treat; MCS, mental
component score; NE, not estimable; NICE, national institute for health and
care excellence; PANSS, positive and negative syndrome scale; PCS, physical
component scale; PETiT, personal evaluation of transitions in treatment;
SD, standard deviation; SF-12, short-form 12; TEAE, treatment-emergent
adverse event
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